Diffuse white matter damage is absent in neuromyelitis optica

American Journal of Neuroradiology

Volumn 31, Issue 1, 2010, Pages 76-79

  Aboul Enein, Fahmy ^a   Krssak M ^b   Hoftberger R ^c   Prayer, D ^b   Kristoferitsch, W ^a  

^a SMZ Ost Donauspital ^*  (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE; CREATININE; IMMUNOGLOBULIN G; N ACETYLASPARTIC ACID;

ADOLESCENT; ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MYELITIS; MYELOOPTIC NEUROPATHY; NORMAL APPEARING WHITE MATTER; PROTON NUCLEAR MAGNETIC RESONANCE; WHITE MATTER;

ADOLESCENT; ADULT; AGED; BRAIN; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; NEUROMYELITIS OPTICA; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 75749120282     PISSN: 01956108     EISSN: None     Source Type: Journal    
DOI: 10.3174/ajnr.A1791     Document Type: Article

References (28)

1. Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol 2007;6:805-15
2. de Seze J, Lebrun C, Stojkovic T, et al. Is Devic's neuromyelitis optica a separate disease?Acomparative study with multiple sclerosis. Mult Scler 2003;9:521-25
3. Weinshenker BG, Wingerchuk DM, Nakashima I, et al. OSMS is NMO, but not MS: proven clinically and pathologically. Lancet Neurol 2006;5:110-11
4. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-89
5. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364:2106-12
6. Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002;125: 1450-61
7. Sinclair C, Kirk J, Herron B, et al. Absence of aquaporin-4 expression in lesions of neuromyelitis optica but increased expression in multiple sclerosis lesions and normal-appearing white matter. Acta Neuropathol 2007;113:187-94
8. Roemer SF, Parisi JE, Lennon VA, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007;130:1194-205
9. Warabi Y, Matsumoto Y, Hayashi H. Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. J Neurol Sci 2007;252:57- 61. Epub 2006 Nov 27
10. Wingerchuk DM, Pittock SJ, Lucchinetti CF, et al.Asecondary progressive clinical course is uncommon in neuromyelitis optica. Neurology 2007;68:603-5
11. Miller DH, Weinshenker BG, Filippi M, et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 2008;14:1157-74
12. Sarchielli P, Presciutti O, Pelliccioli GP, et al. Absolute quantification of brain metabolites by proton magnetic resonance spectroscopy in normal-appearing white matter of multiple sclerosis patients. Brain 1999;122:513-21
13. Wattjes MP, Harzheim M, Kuhl CK, et al. Does high-fieldMRimaging have an influence on the classification of patients with clinically isolated syndromes according to current diagnostic MR imaging criteria for multiple sclerosis? AJNR Am J Neuroradiol 2006;27:1794-98
14. Bagory M, Durand-Dubief F, Ibarrola D, et al. "Absolute" quantification in magnetic resonance spectroscopy: validation of a clinical protocol in multiple sclerosis. Conf Proc IEEE Eng Med Biol Soc 2007;1:3458-61
15. Rigotti DJ, Inglese M, Gonen O. Whole-brain N-acetylaspartate as a surrogate marker of neuronal damage in diffuse neurologic disorders. AJNR Am J Neuroradiol 2007;28:1843-49
16. Bitsch A, Bruhn H, Vougioukas V, et al. Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. AJNR Am J Neuroradiol 1999;20:1619-27
17. Jansen JF, Backes WH, Nicolay K, et al. 1H MR spectroscopy of the brain: absolute quantification of metabolites. Radiology 2006;240:318-32
18. Jarius S, Aboul-Enein F, Waters P, et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 2008;131(Pt 11):3072- 80. Epub 2008 Oct 22
19. Krampla W, Aboul-Enein F, Jecel J, et al. Spinal cord lesions in patients with neuromyelitis optica: a retrospective long-term MRI follow-up study. Eur Radiol 2009;19:2535-43 Epub 2009 May 5
20. Naressi A, Couturier C, Castang I, et al. Java-based graphical user interface for MRUI, a software package for quantitation of in vivo/medical magnetic resonance spectroscopy signals. Comput Biol Med 2001;31:269-86
21. Naressi A, Couturier C, Devos JM, et al. Java-based graphical user interface for the MRUI quantitation package. MAGMA 2001;2:141-52
22. de Beer R, van den Boogaart A, van Ormondt D, et al. Application of time-domain fitting in the quantification of in vivo 1H spectroscopic imaging data sets. NMR Biomed 1992;5:171-78
23. Vanhamme L, van den Boogaart A, Van Huffel S. Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J Magn Reson 1997;129:35-43
24. Wansapura JP, Holland SK, Dunn RS, et al. NMR relaxation times in the human brain at 3.0 Tesla. J Magn Reson Imaging 1999;9:531-38
25. Mlynárik V, Gruber S, Moser E, et al. Proton T (1) and T (2) relaxation times of human brain metabolites at 3 Tesla. NMR Biomed 2001;14:325-31
26. Bichuetti DB, Rivero RL, de Oliveira EM, et al. White matter spectroscopy in neuromyelitis optica: a case control study. J Neurol 2008;255:1895-99
27. Wattjes MP, Harzheim M, Lutterbey GG, et al. Axonal damage but no increased glial cell activity in the normal-appearing white matter of patients with clinically isolated syndromes suggestive of multiple sclerosis using high-field magnetic resonance spectroscopy. AJNR Am J Neuroradiol 2007;28:1517-22
28. B Benedetti B, Rovaris M, Rocca MA, et al. In-vivo evidence for stable neuroaxonal damage in the brain of patients with benign multiple sclerosis. Mult Scler 2009;15:789-94